Tue, Nov 19 · 8:00

In the context of unprecedented gene therapy clinical progress and mounting regulatory scrutiny, the inaugural Gene Therapy Analytical Development Summit will unite large pharma and innovative biotechs to develop robust analytical tools to guarantee the consistency, quality and safety of gene therapy products.

Focused specifically on addressing the unique analytical challenges posed by gene therapy vectors, this technical scientific meeting will unite the ‘boots on the ground’ scientists grappling with these challenges first-hand.

Delving into technical analytics to assess potency, capsid integrity, empty vs full capsids and viral titers of AAV and lentiviral vectors, this is your opportunity to enhance your existing analytical methods and explore innovative novel tools to support safe and effective gene therapy development.

URLs:
Website: https://go.evvnt.com/492574-0?pid=5731
Brochure: https://go.evvnt.com/492574-3?pid=5731

Prices:
Earlybird: USD 1999.0,
Standard: USD 2899.0

Speakers: Peter Marks, FDA, Svetlana Bergelson, Biogen, Wei-Chiang Chen, Solid Biosciences, Win Den Cheung, REGENXBIO, Vivian Choi, Takeda, Pete Clarner, Biogen, Jeffrey Glenn, Spark Therapeutics, Russell Goetze, Bluebird Bio, Joseph Lee, PTC Therapeutics, Lawrence Thompson, Pfizer, Zichuan Zhang, Sanofi, Fengrong Zuo, AveXis, Ales Strancar, BIA Separations, David Malliaros, Ultragenyx